Get the Stockscreener App
38.00
8.57%
3.00
After Hours:
38.00
Mbx Biosciences Inc stock is traded at $38.00, with a volume of 530.66K.
It is up +8.57% in the last 24 hours and up +4.20% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$35.00
Open:
$35.7
24h Volume:
530.66K
Relative Volume:
0.71
Market Cap:
$1.71B
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-24.28
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
+5.41%
1M Performance:
+4.20%
6M Performance:
+203.27%
1Y Performance:
+321.29%
1-Day Range:
$34.71
$38.86
1-Week Range:
$34.06
$39.21
52-Week Range:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
38.00 | 1.57B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences execs join Feb–Mar health investor events - Stock Titan
MBX Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Profit Recap: Is MBX Biosciences Inc being accumulated by smart moneyWeekly Market Report & Community Driven Trade Alerts - baoquankhu1.vn
MBX Biosciences raises $87.1 million through at-the-market stock offering - Investing.com UK
MBX Biosciences raises $87.1 million through at-the-market stock offering By Investing.com - Investing.com South Africa
MBX Biosciences Raises $87 Million in ATM Offering - TipRanks
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MBX Biosciences, Inc. $MBX - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After New Barclays Overweight Coverage - Sahm
How Investors Are Reacting To MBX Biosciences (MBX) Adding Veteran CFO Laurie Stelzer To Its Board - Sahm
MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech Bet With 65.85% Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. (NASDAQ:MBX) Short Interest Update - MarketBeat
MBX Biosciences (NASDAQ:MBX) Now Covered by Analysts at Barclays - MarketBeat
Barclays Initiates Coverage on MBX Biosciences With Overweight Rating - marketscreener.com
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
Risk Off: Is MBX Biosciences Inc part of any ETF2025 Biggest Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a Potential 42.85% Upside in Biotech Innovation - DirectorsTalk Interviews
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return - Yahoo Finance
MBX Biosciences appoints Laurie Stelzer to board of directors By Investing.com - Investing.com Nigeria
MBX Biosciences, Inc. Announces Board and Committee Changes - marketscreener.com
MBX Biosciences appoints Laurie Stelzer to board of directors - Investing.com
MBX Biosciences Appoints Laurie Stelzer to Board, Audit Chair - TipRanks
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair - The Manila Times
Forecast Cut: Should I buy MBX Biosciences Inc stock nowEarnings Overview Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
MBX Biosciences (NASDAQ:MBX) Shares Down 6.8%Here's What Happened - MarketBeat
Assessing MBX Biosciences (MBX) Valuation After Guggenheim’s Supportive Obesity Drug Updates - Sahm
Is MBX Biosciences’ (MBX) Once‑Monthly Obesity Strategy Quietly Redefining Its Competitive Moat? - Sahm
Will MBX Biosciences Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & Long Hold Capital Preservation Tips - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Teladoc (TDOC) and Pfizer (PFE) - The Globe and Mail
Guggenheim raises MBX Biosciences stock price target on obesity drug potential - Investing.com Nigeria
MBX Biosciences Surges Amid Strategic Partnership Developments - timothysykes.com
Breakout Watch: What makes MBX Biosciences Inc stock attractive to growth fundsEarnings Summary Report & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline - Investing.com Canada
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Trading 7.6% HigherTime to Buy? - MarketBeat
MBX Biosciences Sees Shares Surge amid Strategic Partnerships - timothysykes.com
MBX Biosciences Highlights 2026 Outlook and Pipeline Progress - TipRanks
Portfolio Shifts: Is MBX Biosciences Inc stock influenced by commodity pricesJuly 2025 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026 - TradingView — Track All Markets
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Drug maker maps out once-monthly obesity shots and hormone disorder trial - Stock Titan
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):